Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Nexium Case, FDA Pre-Emption Wins; 3rd Circuit Rules For AstraZeneca

This article was originally published in The Tan Sheet

Executive Summary

An appellate court threw out a false advertising suit against AstraZeneca, concluding that since the company's ads complied with FDA-approved labeling, they were not subject to state consumer fraud laws

You may also be interested in...

Federal Pre-emption Defense Under Fire In Draft House Bills

A one-sentence provision tucked into draft House legislation renewing FDA's drug user fee program seeks to weaken manufacturers' ability to use FDA approval as a defense in state product liability lawsuits

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts